Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
TL;DR
Heidelberg Pharma's HDP-101 shows promising anti-tumor activity, offering a potential competitive advantage in treating relapsed multiple myeloma with novel Amanitin-based ADC technology.
HDP-101 is an anti-BCMA antibody-drug conjugate undergoing Phase I/IIa clinical trials to determine optimal dosing and safety for relapsed or refractory multiple myeloma treatment.
This innovative cancer therapy addresses high unmet medical needs in multiple myeloma patients, potentially improving survival and quality of life for those with limited treatment options.
Heidelberg Pharma pioneers using Amanitin from death cap mushrooms in cancer therapy, presenting breakthrough data at the World ADC Congress and hosting a November 11 webinar.
Found this article helpful?
Share it with your network and spread the knowledge!
Heidelberg Pharma AG will present new clinical data from its ongoing Phase I/IIa study of HDP-101, an anti-BCMA antibody-drug conjugate for relapsed or refractory multiple myeloma, at the 16th Annual World ADC Congress in San Diego. The data show objective responses and promising anti-tumor activity observed in several patients across multiple cohorts, reinforcing the therapeutic potential and safety profile of the investigational treatment for this bone marrow cancer with high unmet medical need.
The clinical development represents significant progress in addressing multiple myeloma, a challenging cancer that often becomes resistant to available treatments. Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present an update from patient cohort 8 including efficacy data from the open-label, multicenter study. The presentation titled "From Bench to Breakthrough: The Evolution of Amanitin ADCs - Insights from HDP-101 Phase I/II & the Future of Payload Differentiation" will take place on Wednesday, November 5, 2025, at 5:00 pm PST at the Town & Country San Diego venue.
Following the congress, Heidelberg Pharma will host an R&D webinar on November 11, 2025, at 05:00 pm CET for investors, analysts, and media. The webinar will feature presentations by the Heidelberg Pharma management team alongside Key Opinion Leader Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg and clinical investigator of the study. Participants can register for the webinar using https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2DllA and will have the opportunity to submit questions in advance or during the live event.
HDP-101 represents a novel approach in cancer treatment as Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of this toxin represents a new therapeutic modality used in the company's ATAC technology platform. Multiple myeloma patients who have exhausted standard treatment options represent a population with limited therapeutic alternatives, making the development of innovative approaches like HDP-101 particularly important for improving patient outcomes.
The Phase I portion of the ongoing study is a dose-escalation trial designed to determine the optimal and safe dose level of HDP-101 in preparation for subsequent Phase II clinical evaluation. The promising results observed across multiple patient cohorts suggest potential for this treatment to address the significant medical need in relapsed or refractory multiple myeloma. A recording of the R&D webinar will be accessible via the press and investor section of the company website after the event at www.heidelberg-pharma.com, providing broader access to the clinical data and expert commentary.
Curated from NewMediaWire
